Absolute Antibody Launches VivopureX™ Recombinant Antibodies for *In Vivo* Research

Engineered antibodies available in bulk-discounted sizes improve research results in mouse models

Redcar, UK, January 7, 2020. Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for *in vivo* research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.

VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone's original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.

All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels ideal for *in vivo* applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumor size in a mouse model more effectively than the original rat version.

"The VivopureX™ antibody collection includes a selection of our most exciting mouse-anti-mouse antibodies, now available at discounted bulk prices ideal for *in vivo* researchers," said Dr. Michael Fiebig, Director of Products and Innovations at Absolute Antibody. "Most antibodies currently used *in vivo* are immunogenic, leading to adverse immunological reactions and gradual loss of activity. By applying the same protein engineering approaches used in therapeutic development to research reagents, we can improve *in vivo* research results and further our understanding into the mechanisms underlying immunotherapy."

For more information, and a full list of available antibody targets, please visit our website here.

About Absolute Antibody, Ltd.
Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats.
Visit absoluteantibody.com for more information.

Contact:
Lisa Merolla
Director of Marketing
+1 617-377-4057 (extension 610)
l.merolla@absoluteantibody.com

###